Clinical Trial Update: An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating two fixed doses of SSR149415 (250 mg twice daily and 100 mg twice daily) in patients with major depressive disorder; the study has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• SSR149415

Snippet

Sponsor: Sanofi | Conditions: Depressive Disorder | Phase 2 | Status: COMPLETED